Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356824 | 1.00 | L3MBTL1 (0.47) | L3MBTL1SMN1; SMN2CDK8TSHRHTT | |
| SCHEMBL21395070 | 0.87 | CYP3A4 (0.49) | L3MBTL1TSHRHTTCYP3A4CYP1A2 | |
| SCHEMBL29357070 | 0.87 | L3MBTL1 (0.47) | L3MBTL1CDK8TSHRHTTGRM5 | |
| SCHEMBL21394806 | 0.87 | L3MBTL1 (0.47) | L3MBTL1CDK8TSHRHTTGRM5 | |
| SCHEMBL21395157 | 0.87 | CYP3A4 (0.47) | L3MBTL1TSHRCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL21394809 | 0.86 | TSHR (0.47) | L3MBTL1SMN1; SMN2TSHRCYP3A4CYP1A2 | |
| SCHEMBL29359147 | 0.86 | TSHR (0.47) | L3MBTL1SMN1; SMN2TSHRCYP3A4CYP1A2 | |
| SCHEMBL29355464 | 0.83 | RAB9A (0.47) | SMN1; SMN2CDK8CYP3A4CYP1A2GRM5 | |
| SCHEMBL21394840 | 0.83 | RAB9A (0.47) | SMN1; SMN2CDK8CYP3A4CYP1A2GRM5 | |
| SCHEMBL21394832 | 0.82 | L3MBTL1 (0.47) | L3MBTL1SMN1; SMN2TSHRHTTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-22 | — | — | US | disclosed |
| CN-114174273-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3941908-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-112312913-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | L3MBTL1 3090/4885SMN1; SMN2 121/4885CDK8 1857/4885 |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | L3MBTL1 3366/4885SMN1; SMN2 13/4885CDK8 3589/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | L3MBTL1 3366/4885SMN1; SMN2 13/4885CDK8 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.